Skip to main content

Advertisement

Table 1 Clinical and demographic characteristics

From: Multivariate analysis of brain metabolism reveals chemotherapy effects on prefrontal cerebellar system when related to dorsal attention network

Data/subgroups No CHT (n = 14) CHT (n = 14) p Value a
Age (years) 52 ± 10 52 ± 10 1.00
Gender (M/F) 11/3 11/3 1.00
Education (years) 14 ± 5 14 ± 5 0.96
Type (HL/NHL) 2/12 2/12 1.00
Age at onset (years) 52 ± 10 51 ± 9 0.96
PET localization outside brain (yes/no) 11/3 4/10 0.01
Lymphoma symptoms (yes/no) 5/9 5/9 1.00
Cycles number (n) - 6 ± 3 -
Post-CHT time (months) - 7 ± 9 -
First-line treatmentb (n) - 9 -
Second-line treatment (n) - 5 -
Immunochemotherapy (n) - 10 (7/3)c -
MMSE/30 28.4 ± 1.3 28.1 ± 1.1 0.63
HADS depression/21 4 ± 3 4 ± 3 0.86
HADS anxiety/21 6 ±3 4 ±3 0.17
MADRS/50 9 ± 6 8 ± 7 0.68
DT/10 3 ±2 2 ±2 0.28
  1. CHT, chemotherapy; F, females; HL, Hodgkin's lymphoma; M, males; NHL, non-Hodgkin's lymphoma. a Significance p, for two independent sample t test or p Chi-square test. bFirst-line treatment, ABVD (hydroxydaunorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine) or CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), prednisone or prednisolone). cImmunochemotherapy, treatment plus immunotherapy (rituximab). Values represent, when not otherwise specified, mean ± standard deviation.